| BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair E Hatchi, K Skourti-Stathaki, S Ventz, L Pinello, A Yen, ... Molecular cell 57 (4), 636-647, 2015 | 480 | 2015 |
| TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ... Journal of Clinical Oncology 38 (36), 4274-4282, 2020 | 347 | 2020 |
| The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? AM Vanderbeek, R Rahman, G Fell, S Ventz, T Chen, R Redd, ... Neuro-oncology 20 (8), 1034-1043, 2018 | 130 | 2018 |
| Design and evaluation of an external control arm using prior clinical trials and real-world data S Ventz, A Lai, TF Cloughesy, PY Wen, L Trippa, BM Alexander Clinical Cancer Research 25 (16), 4993-5001, 2019 | 73 | 2019 |
| Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications R Rahman, G Fell, S Ventz, A Arfé, AM Vanderbeek, L Trippa, ... Clinical Cancer Research 25 (21), 6339-6345, 2019 | 66 | 2019 |
| Leveraging external data in the design and analysis of clinical trials in neuro-oncology R Rahman, S Ventz, J McDunn, B Louv, I Reyes-Rivera, MYC Polley, ... The Lancet Oncology 22 (10), e456-e465, 2021 | 63 | 2021 |
| TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib … NM Tung, ME Robson, S Ventz, CA Santa-Maria, PK Marcom, R Nanda, ... Journal of Clinical Oncology 38 (15_suppl), 1002-1002, 2020 | 60 | 2020 |
| Bayesian response-adaptive designs for basket trials S Ventz, WT Barry, G Parmigiani, L Trippa Biometrics 73 (3), 905-915, 2017 | 53 | 2017 |
| A Bayesian method for detecting pairwise associations in compositional data E Schwager, H Mallick, S Ventz, C Huttenhower PLoS computational biology 13 (11), e1005852, 2017 | 47 | 2017 |
| Bayesian designs and the control of frequentist characteristics: a practical solution S Ventz, L Trippa Biometrics 71 (1), 218-226, 2015 | 47 | 2015 |
| A Bayesian response-adaptive trial in tuberculosis: The endTB trial M Cellamare, S Ventz, E Baudin, CD Mitnick, L Trippa Clinical Trials 14 (1), 17-28, 2017 | 41 | 2017 |
| The use of external control data for predictions and futility interim analyses in clinical trials S Ventz, L Comment, B Louv, R Rahman, PY Wen, BM Alexander, ... Neuro-oncology 24 (2), 247-256, 2022 | 35 | 2022 |
| Designing clinical trials that accept new arms: an example in metastatic breast cancer S Ventz, BM Alexander, G Parmigiani, RD Gelber, L Trippa Journal of Clinical Oncology 35 (27), 3160-3168, 2017 | 34 | 2017 |
| Lessons learned from deescalation trials in favorable risk HPV-associated squamous cell head and neck cancer–a perspective on future trial designs S Ventz, L Trippa, JD Schoenfeld Clinical Cancer Research 25 (24), 7281-7286, 2019 | 26 | 2019 |
| To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs AM Vanderbeek, S Ventz, R Rahman, G Fell, TF Cloughesy, PY Wen, ... Neuro-oncology 21 (10), 1239-1249, 2019 | 23 | 2019 |
| Adding experimental arms to platform clinical trials: randomization procedures and interim analyses S Ventz, M Cellamare, G Parmigiani, L Trippa Biostatistics 19 (2), 199-215, 2018 | 22 | 2018 |
| Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial M Cellamare, M Milstein, S Ventz, E Baudin, L Trippa, CD Mitnick The International Journal of Tuberculosis and Lung Disease 20 (12), S8-S12, 2016 | 22 | 2016 |
| A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly S Tabrizi, L Trippa, D Cagney, S Tanguturi, S Ventz, G Fell, PY Wen, ... Neuro-oncology 22 (7), 918-927, 2020 | 17 | 2020 |
| Bayesian uncertainty directed trial designs S Ventz, M Cellamare, S Bacallado, L Trippa Journal of the American Statistical Association 114 (527), 962-974, 2019 | 17 | 2019 |
| The design and evaluation of hybrid controlled trials that leverage external data and randomization S Ventz, S Khozin, B Louv, J Sands, PY Wen, R Rahman, L Comment, ... Nature communications 13 (1), 5783, 2022 | 13 | 2022 |
